THE 2-MINUTE RULE FOR ABBV-744 AND OTHER BRD4 INHIBITORS COMPARISON

The current work examined the potential of making use of ARV-825 and ABBV-744 to raise the effectiveness of tamoxifen or fulvestrant furthermore palbociclib. ARV-825 was effective in the two p53 wild-type (WT) breast tumor cells As well as in cells missing useful p53 both alone or in combination with tamoxifen, though the effectiveness of ABBV-744